NEW YORK (360Dx) – Critical Diagnostics today announced the completion of a financing round that raised $8.5 million.
The funding will be used to continue global commercialization efforts, the San Diego-based firm said, adding the financing was raised by a consortium of unnamed investors.
Critical Diagnostics makes the Presage ST2 Assay and Aspect-Plus ST2 test, which are used to manage heart failure patients. ST2 is a protein expressed by the hear in response to disease or injury. The company licensed intellectual property around ST2 from Brigham and Women's Hospital, and the Presage ST2 test is FDA cleared and CE marked, it said.